Why GLP-1 Medications Like Ozempic Have Surprising Side Effects

By VirentaNews Staff — May 12, 2026

Executive summary: The increasing popularity of GLP-1 drugs, such as Ozempic, has led to a growing concern about their potential side effects. A recent study has identified several “hidden” side effects of these medications, including chills, hot flashes, and irregular periods, through self-reporting among Reddit users. These findings highlight the need for further research into the long-term effects of GLP-1 treatments and the importance of monitoring patient experiences.

Evidence of Hidden Side Effects

The study, which analyzed self-reported data from Reddit users, found that many patients taking GLP-1 drugs experienced a range of unexpected side effects. These included chills, hot flashes, and irregular periods, as well as other symptoms such as nausea, diarrhea, and fatigue. The research suggests that these side effects may be more common than previously thought, and that patients and healthcare providers should be aware of the potential risks associated with GLP-1 treatments. According to the National Institutes of Health, GLP-1 drugs work by mimicking a natural hormone in the body that helps to regulate blood sugar levels.

Key Players in the GLP-1 Market

The GLP-1 market is dominated by several key players, including Novo Nordisk, the manufacturer of Ozempic. Other major pharmaceutical companies, such as Eli Lilly and AstraZeneca, also produce GLP-1 treatments. These companies have a significant interest in the ongoing research into the safety and efficacy of GLP-1 drugs, as the market for these medications is expected to continue growing in the coming years. As reported by Reuters, the global GLP-1 market is projected to reach $10 billion by 2025.

Trade-Offs of GLP-1 Treatments

While GLP-1 drugs have been shown to be effective in managing type 2 diabetes and obesity, they also carry potential risks and side effects. Patients taking these medications must weigh the benefits of improved blood sugar control and weight loss against the potential costs of unexpected side effects. Healthcare providers must also consider the trade-offs when prescribing GLP-1 treatments, taking into account the individual needs and medical history of each patient. The Centers for Disease Control and Prevention provide guidance on the safe use of GLP-1 drugs and the importance of monitoring patient health.

Timing of the Study

The study’s findings come at a time when the use of GLP-1 drugs is becoming increasingly widespread. As the prevalence of type 2 diabetes and obesity continues to rise, the demand for effective treatments is growing. The identification of hidden side effects highlights the need for ongoing research into the long-term effects of GLP-1 treatments and the importance of monitoring patient experiences. According to the World Health Organization, the global prevalence of diabetes is expected to reach 578 million by 2030.

Where We Go From Here

Looking ahead to the next 6-12 months, there are several possible scenarios for the GLP-1 market. One scenario is that the identification of hidden side effects will lead to increased scrutiny of GLP-1 treatments, potentially slowing their adoption. Another scenario is that the findings will prompt further research into the safety and efficacy of these medications, leading to improved patient outcomes. A third scenario is that the GLP-1 market will continue to grow, driven by the increasing demand for effective treatments for type 2 diabetes and obesity.

Bottom line: The study’s findings highlight the need for ongoing research into the long-term effects of GLP-1 treatments and the importance of monitoring patient experiences, as the use of these medications becomes increasingly widespread.

Source: Healthline